欢迎您访问中乔新舟官网!400-038-9959我的购物车(0)
您当前的位置:首页 > 产品中心
SW872人脂肪肉瘤细胞 (STR鉴定)
英文名:SW872
货号:ZQ0722
价格:¥3200.00
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

SW872人脂肪肉瘤细胞 (STR鉴定)

¥3200.00
+

SW872人脂肪肉瘤细胞专用培养基

¥350.00 ¥550.00

配套完培,省时省力,单买细胞无优惠

=

细胞套餐惊爆价

¥3550 ¥2150.00
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

SW872人脂肪肉瘤细胞

货号

ZQ0722

产品介绍

SW872是一种人脂肪肉瘤细胞系,最初由A. Leibovitz在1974年从一个36岁男性的脂肪肉瘤手术样本中建立。这种细胞系属于软组织肉瘤的亚型,即脂肪肉瘤,源自脂肪细胞的恶性转化。SW872细胞表现为贴壁生长的成纤维细胞样形态,并广泛应用于癌症研究,尤其是肿瘤的生物学特性和机制研究。

种属

性别/年龄

/36岁

组织

结缔组织

疾病

脂肪肉瘤

细胞类型

肿瘤细胞

形态学

成纤维样

生长方式

贴壁

倍增时间

大约24 hours (PubMed=16888811)

培养基和添加剂

DMEM高糖基础培养基(品牌:中乔新舟 货号:ZQ-100+10%胎牛血清(中乔新舟  货号:AU0600+1%P/S(中乔新舟  货号:CSP006

推荐完全培养基货号

ZM0722

生物安全等级

BSL-1

培养条件

5%二氧化碳;37℃

STR位点信息

Amelogenin: X

CSF1PO: 10

D2S1338 17,21

D3S1358 16

D5S818 12,13

D7S820 8,11

D8S1179 12,15

D13S317 11

D16S539 9,12

D18S51 12,16

D19S433 13,14

D21S11 27,31.2

FGA 21.2,23

Penta D 9,10

Penta E 5,10

TH01 8,10

TPOX 8,11

vWA 17

抗原表达/受体表达

*** 

基因表达

*** 

保藏机构

ATCC; HTB-92;BCRC; 60432

供应限制

仅供科研使用


货号

ZQ0722

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)


PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)


PubMed=6220172
Dracopoli N.C., Fogh J.
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983)


PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)


PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)


PubMed=16888811; DOI=10.1002/jcb.21073
Moneo V., Serelde B.G., Fominaya J.M., Martinez-Leal J.F., Blanco-Aparicio C., Romero L., Sanchez-Beato M., Cigudosa J.C., Tercero J.C., Piris M.A., Jimeno J.M., Carnero A.
Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.
J. Cell. Biochem. 100:339-348(2007)


PubMed=17354236; DOI=10.1002/ijc.22643
Muller C.R., Paulsen E.B., Noordhuis P., Pedeutour F., Saeter G., Myklebost O.
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.
Int. J. Cancer 121:199-205(2007)


PubMed=17426441; DOI=10.4161/cbt.6.4.3816
LaPensee E.W., Reddy S.P., Hugo E.R., Schwemberger S.J., Ben-Jonathan N.
LS14 cells: a model for chemoresistance in liposarcoma.
Cancer Biol. Ther. 6:519-524(2007)


PubMed=17431109; DOI=10.1158/1535-7163.MCT-06-0729
Moneo V., Serelde B.G., Leal J.F.M., Blanco-Aparicio C., Diaz-Uriarte R., Aracil M., Tercero J.C., Jimeno J.M., Carnero A.
Levels of p27(kip1) determine Aplidin sensitivity.
Mol. Cancer Ther. 6:1310-1316(2007)


PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)


PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)


PubMed=22911243; DOI=10.1155/2012/148614
Stratford E.W., Castro R., Daffinrud J., Skarn M., Lauvrak S., Munthe E., Myklebost O.
Characterization of liposarcoma cell lines for preclinical and biological studies.
Sarcoma 2012:148614.1-148614.9(2012)


PubMed=24726063; DOI=10.1186/1756-9966-33-33
Koelsche C., Renner M., Hartmann W., Brandt R., Lehner B., Waldburger N., Alldinger I., Schmitt T., Egerer G., Penzel R., Wardelmann E., Schirmacher P., von Deimling A., Mechtersheimer G.
TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities.
J. Exp. Clin. Cancer Res. 33:33.1-33.8(2014)


PubMed=24758355; DOI=10.1186/1471-2407-14-281
Moneo V., Serelde B.G., Blanco-Aparicio C., Diaz-Uriarte R., Aviles P., Santamaria G., Tercero J.C., Cuevas C., Carnero A.
Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis.
BMC Cancer 14:281.1-281.10(2014)


PubMed=26643872; DOI=10.18632/oncotarget.6464
Kanojia D., Nagata Y., Garg M., Lee D.H., Sato A., Yoshida K., Sato Y., Sanada M., Mayakonda A., Bartenhagen C., Klein H.-U., Doan N.B., Said J.W., Mohith S., Gunasekar S., Shiraishi Y., Chiba K., Tanaka H., Miyano S., Myklebost O., Yang H., Dugas M., Meza-Zepeda L.A., Silberman A.W., Forscher C., Tyner J.W., Ogawa S., Koeffler H.P.
Genomic landscape of liposarcoma.
Oncotarget 6:42429-42444(2015)


PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)


PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)


PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)


PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

暂无相关产品!
公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
           上海中乔新舟生物科技有限公司(官网:www.zqxzbio.com)成立于2011年,历经...
联系我们 / Contact
电 话:021-56760357;021-56760351
传 真:
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved.
技术支持:中乔新舟沪ICP备14008091号